Get the Stockscreener App
29.20
2.60%
-0.78
After Hours:
29.58
0.38
+1.30%
Anbio Biotechnology stock is traded at $29.20, with a volume of 30,212.
It is down -2.60% in the last 24 hours and up +12.96% over the past month.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
See More
Previous Close:
$29.98
Open:
$31
24h Volume:
30,212
Relative Volume:
0.65
Market Cap:
$1.28B
Revenue:
$9.74M
Net Income/Loss:
$7.19M
P/E Ratio:
178.38
EPS:
0.1637
Net Cash Flow:
$2.25M
1W Performance:
+5.00%
1M Performance:
+12.96%
6M Performance:
+32.73%
1Y Performance:
+362.76%
1-Day Range:
$29.00
$32.70
1-Week Range:
$27.16
$32.94
52-Week Range:
$6.24
$55.65
Anbio Biotechnology Stock (NNNN) Company Profile
Name
Anbio Biotechnology
Sector
Industry
Phone
-
Address
-
Compare NNNN vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
29.20 | 1.32B | 9.74M | 7.19M | 2.25M | 0.1637 |
ISRG
Intuitive Surgical Inc
|
451.38 | 160.21B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.17 | 41.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.32 | 37.37B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.45 | 35.82B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
207.88 | 30.38B | 5.40B | 1.49B | 1.78B | 10.12 |
Anbio Biotechnology Stock (NNNN) Latest News
Why Anbio Biotechnology Class A Shares Are Surging - TipRanks
Why Anbio Biotechnology Class A Shares Are Jumping - TipRanks
Free cash flow per share of Anbio Biotechnology Class A – FWB:N3B - TradingView
Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul - TipRanks
Anbio Biotechnology (NNNN) seeks huge capital increase and 500-vote Class B shares - Stock Titan
Why Anbio Biotechnology Class A Shares Keep Sliding - TipRanks
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
Why Anbio Biotechnology Shares Are Suddenly Surging - TipRanks
Anbio (NNNN) Stock Volume Drop (Buying Pressure) 2026-04-22Trending Buy Opportunities - Newser
Anbio Biotechnology posts solid FY25 results, diversifies portfolio - MSN
Cany Xu Net Worth (2026) - GuruFocus
Nancy Hartzler Net Worth (2026) - GuruFocus
Suki Song Net Worth (2026) - GuruFocus
Michael Lau Net Worth (2026) - GuruFocus
Chris Tian Net Worth (2026) - GuruFocus
Why Anbio Biotechnology Shares Are Sliding Fast - TipRanks
Anbio Biotechnology (NASDAQ:NNNN) Trading Down 5.5%Here's What Happened - MarketBeat
Assessing Anbio Biotechnology (NNNN) Valuation After Sharp Swings And A Rich Price To Book Multiple - simplywall.st
Anbio Biotechnology Broadens Test Portfolio And Shifts Risk Profile - Sahm
Is Anbio (NNNN) Stock Discounted Now | Price at $27.63, Up 1.96%Verified Stock Signals - Newser
Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio - Sahm
Is Anbio (NNNN) Stock Good for Beginners | Price at $26.77, Down 0.28%Verified Stock Signals - Newser
Form 20-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] - ADVFN
Discovering US Undiscovered Gems for April 2026 - simplywall.st
Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer - Stock Titan
Anbio Biotechnology (ANBF) Non Cash 74.1% Net Margin Fuels Fresh Debate On Earnings Quality - simplywall.st
Anbio Biotechnology | 3: Initial statement of beneficial ownership of securities- Hartzler Nancy - Moomoo
Anbio Biotechnology (NNNN) CEO Michael Lau identified as insider in Form 3 - Stock Titan
Anbio Biotechnology (NNNN) director XU CANY files initial Form 3 - Stock Titan
Why Anbio Biotechnology Class A Shares Are Sinking - TipRanks
Super-voting control and post-COVID shift at Anbio Biotechnology (Nasdaq: NNNN) - Stock Titan
Anbio Biotechnology Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Will Anbio (NNNN) Stock Hit New Highs | Price at $26.40, Up 2.13%Community Trade Ideas - Newser
Exxon Mobil, Pepsico among market cap stock movers on Monday - Investing.com UK
Exxon Mobil, Pepsico among market cap stock movers on Monday By Investing.com - Investing.com Canada
Anbio Biotechnology (NNNN) Surges 11.6% Intraday – What’s Fueling the Volatility? - Bitget
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum - The Manila Times
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum on March 17, 2026 - geneonline.com
Anbio CEO to outline rapid diagnostic plans at KeyBanc investor event - Stock Titan
Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review - Defense World
Anbio Biotechnology and Oncocyte Compared in Financial Analysis - National Today
Anbio Biotechnology falls -5.8% - MSN
Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Anbio Biotechnology Stock Quote, Share Price, News and Analysis - Longbridge
Head to Head Contrast: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Anbio Biotechnology (NASDAQ:NNNN) vs. Oncocyte (NASDAQ:IMDX) Critical Comparison - Defense World
TechTarget (TTGT) to Release Earnings on Wednesday - Defense World
Anbio Biotechnology Stock (NNNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):